Fundraising FoxImmunomet Therapeutics
Houston, US · Delaware corporation
Find your way into Immunomet Therapeutics
Sign up to see every warm intro you have to Immunomet Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Immunomet Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
ImmunoMet Therapeutics is a clinical-stage oncology drug developer working to advance lixumistat, a compound targeting oxidative phosphorylation in cancer to address resistance to existing treatments. Founded in 2015 as a spin-off from HanAll Biopharma, the company runs its clinical programs with specialist CROs and partners, including trials at MD Anderson Cancer Center.
Founders & leadership
Reported raises · per SEC filings
Form D private placements$842.2K disclosed across 1 round · 2026
▶$842.2KraisedFeb 2026 · 4 investors · BiotechnologyRule 506(b)
▶$842.2KraisedFeb 2026 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dean WelschExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $842.2K
- Proceeds to insiders
- $220K
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 6
ImmunomeImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
Immunomic TherapeuticsImmunomic Therapeutics develops nucleic acid immunotherapy platforms, particularly self-amplifying RNA and plasmid DNA vaccines, for cancer treatment, allergies, and animal health applications. The company's UNITE® platform leverages lysosomal targeting technology to generate immune responses against CMV, HPV, and other tumor-associated antigens across multiple cancer types and allergic conditions.
ImmuneeringImmuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.
Immune-Onc TherapeuticsImmune Onc is a biotechnology company developing medicines to treat patients with hard-to-treat cancers and autoimmune diseases, with expertise in translational medicine and clinical development.
InimmuneInimmune is a clinical-stage biotech company developing immunotherapies for allergy, cancer, infectious, and autoimmune diseases. The company combines immunology and vaccine expertise to advance its clinical and pre-clinical pipeline.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as Immunomet Therapeutics.
In the news
Frequently asked questions
- What does Immunomet Therapeutics do?
- ImmunoMet Therapeutics is a clinical-stage oncology drug developer working to advance lixumistat, a compound targeting oxidative phosphorylation in cancer to address resistance to existing treatments. Founded in 2015 as a spin-off from HanAll Biopharma, the company runs its clinical programs with specialist CROs and partners, including trials at MD Anderson Cancer Center.
- How much funding has Immunomet Therapeutics raised?
- Immunomet Therapeutics has disclosed $842.2K raised across 1 round.
- Where is Immunomet Therapeutics headquartered?
- Immunomet Therapeutics is headquartered in Houston, US.